Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company announces its Orthopaedics for All
initiative – a global advisory board established to amplify
diversity by building equity, breaking biases, and inspiring
inclusion for individuals wishing to pursue a career in orthopaedic
surgery.
The disparity of women in the field of orthopaedic surgery
compared to men is staggering. According to multiple studies, only
15% of all orthopaedic residents were women and just 7.4% were
practicing orthopaedic surgeons in the United States during 2022.
Several factors may contribute to this inequity including greater
vulnerability to work-family conflict, less supportive references
than their male counterparts, and less national research funding
compared to men. Smith+Nephew aims to address these long-standing
challenges headfirst and help set new standards in patient centric
care.
Board member Dr. Jessica Hooper, Clinical Assistant Professor,
Department of Orthopaedic Surgery at Stanford Health Care
commented, “Orthopaedics for All, to me, means giving everybody a
voice in our field and direction on where we’re going in the
future.”
The Smith+Nephew Orthopaedics for All global advisory board is
comprised of approximately twenty leading female key opinion
leaders and surgeons in the adult hip and knee orthopaedic
reconstruction segment and includes representatives from all over
the world. Board members must have a minimum of two years
post-fellowship experience in reconstructive surgery, a mix of both
academic and private practice experience, and an interest in gender
diversity and inclusion initiatives. Orthopaedics for All will also
drive awareness in the greater orthopaedic surgeon community around
the technical skills and competence female orthopaedic surgeons
possess.
Smith+Nephew’s Chief Human Resource Officer Elga Lohler
commented, “There is meaningful data that supports the case for
increased diversity within medicine and more broadly the medical
device industry. Diversifying our work force is not just critical
to improving employee engagement and retention, which directly
impacts business growth and profitability, but diversity in
medicine can also help reduce health care disparity and improve
patient outcomes. Our Orthopaedics for All global advisory board
has been established to truly understand the needs of a more
diverse customer group, so that we can build sustainable strategies
that address rapidly evolving customer needs.”
Board member Ms. Chloe Scott, Consultant Orthopaedic Surgeon at
Edinburgh Orthopaedic Specialists, UK explained, “I’m really
excited to be a part of Orthopaedics for All. I think Smith+Nephew
has gone a step further than the other companies in terms of
actually being proactive to improve engagement with women in
arthroplasty, which is really refreshing to see.”
Smith+Nephew recently partnered with the Perry Initiative who
hosted forty female high school students at Wake Forest School of
Medicine to explore hands-on surgery modules and receive mentorship
from women surgeons and engineers. The Perry Initiative inspires
young women to be leaders in orthopaedic surgery and engineering by
partnering with medical centers, universities and high schools
across the US.
“The Smith+Nephew Orthopaedics for All advisory board gives
women in arthroplasty a voice and a wonderful chance to contribute
to the field of arthroplasty, much like the Perry Initiative gives
opportunities to individuals interested in engineering and
orthopaedics,” commented Antonia F. Chen, MD, Chief of Arthroplasty
and Joint Reconstruction, Brigham and Women's Hospital and
Associate Professor of Orthopaedic Surgery, Harvard Medical
School.
To learn more about Smith+Nephew and our purpose of ‘Life
Unlimited’, please visit www.smith-nephew.com.
- ends –
Media Enquiries Dave Snyder
+1 (978)
749-1440 Smith+Nephew
david.snyder@smith-nephew.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading profit margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: conflicts
in Europe and the Middle East, economic and financial conditions in
the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and
innovative medical devices; developments in medical technology;
regulatory approvals, reimbursement decisions or other government
actions; product defects or recalls or other problems with quality
management systems or failure to comply with related regulations;
litigation relating to patent or other claims; legal and financial
compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of
our suppliers; competition for qualified personnel; strategic
actions, including acquisitions and disposals, our success in
performing due diligence, valuing and integrating acquired
businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to
market developments; relationships with healthcare professionals;
reliance on information technology and cybersecurity; disruptions
due to natural disasters, weather and climate change related
events; changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC’s website at www. sec.gov, for
a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
Smith and Nephew (NYSE:SNN)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Smith and Nephew (NYSE:SNN)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
